<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00941135</url>
  </required_header>
  <id_info>
    <org_study_id>HN2008</org_study_id>
    <secondary_id>EudraCT number: 2008-003365-29</secondary_id>
    <nct_id>NCT00941135</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study in Patients With Local Advanced Larynx/Hypolarynx Carcinoma Treated With TPF Induction Chemotherapy Followed by Hyperfractionated Radiotherapy With Cetuximab</brief_title>
  <official_title>Phase II Study of TPF Induction Chemotherapy Followed by Hyperfractionated Radiotherapy With Cetuximab &quot;Boost Concomitant&quot; With Cetuximab in Patients With Local Advanced Larynx/Hypolarynx Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion Miguel Servet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Salutis Research, SL</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Unidad de Genética Clínica (Clínica Universitaria de Navarra)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundacion Miguel Servet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the progression free time in patients with completed or partial response &gt; 30%
      evaluated over primary tumour (damage T and N) after induction TPF (Docetaxel, Cisplatin,
      5-FU) treated with RT + Cetuximab over 2 years.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Anticipated">May 2013</completion_date>
  <primary_completion_date type="Anticipated">May 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate progression-free time in patients with complete or partial response &gt;30% evaluated over primary tumour(T and N) after TPF induction treated with RT + Cetuximab.</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Laryngeal Neoplasms</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Docetaxel+Cisplatin+5-FU+ Radiotherapy+Cetuximab</intervention_name>
    <description>Docetaxel:75 mg/m2/d IV Cisplatin:75 mg/m2/d IV 5-FU:750 mg/m2/d IV TPF 3 cycles every 3 weeks
Radiotherapy: Total 72 Gy in 42 fractions Cetuximab: 250 mg/m2/d Days 1, 8, 15, 22, 29, 36 and 43</description>
    <other_name>TPF (Chemotherapy Regimen code)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient informed consent must be signed before to start the study.

          -  Age between 18 to 70 years.

          -  Performance Status 0-1 according to ECOG scale at the moment of inclusion.

          -  Life expectancy &gt;3 months.

          -  Confirmed anatomopathologic diagnosis of local advance scaly larynx or hypolarynx
             carcinoma III or IV stage without evidence of distance metastasis, which surgery
             involve a total laryngectomy.

          -  T3, T4A, T4B or T2 not candidate to a partial laryngectomy. In case of T2 of both
             locations it will be required III or IVA stage.

          -  Patients in medical conditions to receive neoadjuvant treatment with TPF followed by
             hyperfractionated radiotherapy combined with cetuximab.

          -  Presence of a injury measurable with RECIST criteria.

          -  Neutrophils &gt; or = 1500/mm3, platelets &gt; or = 150.000/mm3 and haemoglobin &gt; or =10
             g/dL.

          -  Renal Function appropriate

          -  Hepatic Function appropriate

          -  Serum Calcium tight to albumine &lt; or = 1,25 x upper normal limit (UNL).

          -  Nutritional status appropriate: weight loss &lt; 20% and albumine &gt; or = 35 g/L.

          -  Women of childbearing potential and men must agree to use adequate contraception prior
             to study entry and for the duration of study participation.

        Exclusion Criteria:

          -  Metastatic disease.

          -  Surgical treatment, radiotherapy and/or previous chemotherapy.

          -  Another tumour locations in head and neck area different from larynx or hypo larynx.

          -  Another stages different from III or IVa without distant metastasis and resectable
             disease.

          -  Another previous scaly carcinoma

          -  Diagnosis of another neoplasia in last 5 years, except cervix carcinoma in situ and/or
             basocellular cutaneous carcinoma adequately treated.

          -  Active infection treated by ATB IV, including active tuberculosis and VIH.

          -  Hypertension not controled defined as systolic &gt; or = 180 mm Hg and/or diastolic &gt; or
             =130 mm Hg at rest.

          -  Pregnant/lactating women.

          -  Systemic immune treatment, chronic and concomitant, or cancer hormone treatment.

          -  Another antineoplastics concomitant treatments.

          -  Coronary artery disease or history of heart attack in the last 12 months or high risk
             of arrythmia uncontrolled or cardiac insufficiency uncontrolled.

          -  EPOC that required more than 3 hospitalizations in the last 12 months.

          -  Active ulcus not controled.

          -  Psychiatric illness/social situations that would limit compliance with study
             requirements

          -  Drug abuse (except alcohol abuse)

          -  Knowledge of Allergic to study treatment.

          -  Previous treatment with Monoclonal antibodies.

          -  Any experimental treatment in the previous 30 days to start the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fernando Arias, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Navarra</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ruth Vera, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Navarra</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Carlos Haya</name>
      <address>
        <city>Malaga</city>
        <state>Andalucía</state>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Universitaria de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundación Jiménez Díaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 15, 2009</study_first_submitted>
  <study_first_submitted_qc>July 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2009</study_first_posted>
  <last_update_submitted>September 28, 2011</last_update_submitted>
  <last_update_submitted_qc>September 28, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 29, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Laryngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

